ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022

September 3, 2021 GMT

VICTORIA, British Columbia--(BUSINESS WIRE)--Sep 3, 2021--

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a pre-submitted question-and-answer period. Investors interested in submitting questions ahead of the call are encouraged to email the Company’s investor relations representative.

Conference Call:

Date: September 9, 2021
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: 1-877-407-3982
International dial-in number: 1-201-493-6780
Conference ID: 13722893
Webcast:http://public.viavid.com/index.php?id=146463

ADVERTISEMENT

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at https://www.immunoprecise.com/investors.

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

ImmunoPrecise Antibodies Ltd.

ADVERTISEMENT

ImmunoPrecise is an innovation-driven technology platform company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of classes of disease targets. The Company aims to transform the conventional multi-vendor antibody discovery model by providing a comprehensive suite of services tailored to optimize antibody genetic diversity and epitope coverage, to discover antibodies against rare and/or challenging epitopes. For further information, visit www.immunoprecise.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210903005055/en/

CONTACT: Investors:

LifeSci Advisors

John Mullaly

Email:jmullaly@lifesciadvisors.com

KEYWORD: UNITED STATES NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES GENETICS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: ImmunoPrecise Antibodies Ltd.

Copyright Business Wire 2021.

PUB: 09/03/2021 08:28 AM/DISC: 09/03/2021 08:28 AM

http://www.businesswire.com/news/home/20210903005055/en